Abstract MSCs are promising candidates for stem cell therapy and regenerative medicine. Umbilical cord is the easiest obtainable biological source of MSCs and the Wharton's jelly of the umbilical cord is a rich source of fetus-derived stem cells. However, the use of MSCs for therapeutic application is based on their subsequent large-scale in vitro expansion. A fast and efficient protocol for generation of large quantities of MSCs is required to meet the clinical demand and biomedical research needs. Here we have optimized conditions for scaling up of WJ-MSCs. Low seeding density along with basic fibroblast growth factor (bFGF) supplementation in the growth medium, which is DMEM-KO, resulted in propagation of more than 1x10 8 cells within a time period of 15 days from a single umbilical cord. The upscaled WJ-MSCs retained their differentiation potential and immunosuppressive capacity. They expressed the typical hMSC surface antigens and the addition of bFGF in the culture medium did not affect the expression levels of HLA-DR and CD 44. A normal karyotype was confirmed in the large-scale expanded WJ-MSCs. Hence, in this study we attempted rapid clinical-scale expansion of WJ-MSCs which would allow these fetus-derived stem cells to be used for various allogeneic cell-based transplantations and tissue engineering.
Introduction
Mesenchymal stem cells or multipotent stromal cells (MSCs) are adult mulitpotent cells which have been isolated from almost every type of connective tissue (da Silva Meirelles et al., 2006) . They can self-renew and under appropriate in vitro conditions have the capacity to differentiate into mesodermal, endodermal, and even ectrodermal lineages (Pittenger et al., 1999; Lakshmipathy and Verfaillie, 2005) . They evoke only minimal immunoreactivity (Tse et al., 2003) and secrete bioactive factors with anti-inflammatory and immunomodulatory effects in vivo (Le Blanc, 2003; Caplan and Dennis, 2006) . Hence, MSCs appear to have a remarkable clinical potential in tissue regeneration and immunoregulatory therapeutic applications.
MSCs were first identified by Friedenstein and his colleagues as fibroblast-like cells with clonogenic potential residing in rat bone marrow (Friedenstein et al., 1966) . To date, the best characterized source of MSCs is the bone marrow (BM) and most of the knowledge regarding MSCs is based on BM studies. However, processing and harvesting of MSCs from BM has certain limitations such as being a highly invasive procedure to the donors and there is a sharp decrease in number of MSCs per nucleated marrow cell with age. Again, the multipotent differentiation potential and proliferation efficiency of BM-MSCs decline with increasing age (Stenderup et al., 2003; Mueller and Glowacki, 2001 ). There are now various other sources of MSCs and one such alternative source is the umbilical cord which, though a fetusderived tissue, can be easily obtained and processed and is noncontroversial. Wharton's jelly (WJ) is the connective tissue between the umbilical cord vessels and WJ-derived MSCs possess multipotent properties between embryonic stem cells and adult stem cells (Bongso et al., 2008) . They have a higher proliferation rate and self-renewal capacity compared to adult stem cells (Can and Karahuseyinoglu, 2007) . Thus, WJ-MSCs have the potential to act as cellular therapy in transplantation and regenerative medicine.
MSCs are currently being used in a number of animal models for human diseases and tested in several clinical trials (Schwarz et al., 1999; Schwarz et al., 2001; Ringden et al., 2006; Mazzini et al., 2006; Koc et al., 2002; Numaguchi et al., 2006) . However, MSC transplantation requires harvesting a large number of cells. They are present in very low percentages in their niches and a vast number of cells are required to provide sufficient quantity for subsequent therapeutic applications. MSC seeding density as well as choice of medium and type of tissue culture plastic can influence cell proliferation (Sotiropoulou et al., 2006) . It has been reported previously that human cells proliferate most rapidly and maximally retain the multipotentiality when seeded at low densities (Colter et al., 2000; Sekiya et al., 2002) . Basic fibroblast growth factor (bFGF) is a well-established growth factor which can enhance cell proliferation. There are reports of bFGF being used as a potent mitogen for MSCs in culture while maintaining their differentiation potential and telomere length (Van den Bos et al., 1997; Tsutsumi et al., 2001) . That MSCs enter senescence almost undetectably from the moment of in vitro culturing was reported earlier and hence, it is much better to consider them for cell and gene therapy early on (Bonab et al., 2006) . Again, large-scale in vitro expansion may lead to genetic and epigenetic instabilities. Although, human MSCs are not prone to spontaneous transformations and quite a few reports suggest normal karyotypes and DNA copy numbers in long-term cultures of MSCs (Tonti and Mannello, 2008) , emergence of tumorogenic populations on in vitro culture of bone marrow human MSCs has been described (Wang et al., 2005) .
We had earlier described a protocol for upscaling WJ-MSCs and attaining 4-5×10 9 cells in 5-6 passages from a single cord (Nekanti et al., 2010) . Here, we modified and optimized the protocol for the large-scale production of WJ-MSCs which reproducibly resulted in more than 1 × 10 8 cells from a single umbilical cord by passage 1 or within 15 days. We have analyzed the multilineage differentiation behavior and cell surface markers of the upscaled MSCs. In addition, the upscaled WJ-MSCs expressed the mesenchymal stem cell/progenitor marker STRO-1 and the pluripotency marker OCT-4. To exclude the possibility that large-scale expansion can affect immunosuppressive ability, the influence of upscaled WJ-MSCs on PHA-driven lymphocyte proliferation was determined. Karyotype analysis was performed to evaluate numerical and structural abnormalities, if any, in the large-scale expanded WJ-MSCs and also, they were assessed for the expression of oncogenes and tumor-suppressor genes.
Hence, here we present optimal culture conditions to generate clinical quantities of human WJ-derived MSCs with retained differentiation potential, immunosuppressive capacity, and chromosomal stability.
Results
Experiments were carried our using three separate sets of WJ-MSC samples. The first set was used to standardize seeding density, the second set was used to establish bFGF concentrations, and the third set was used to conduct the clinical-scale expansion.
Effect of seeding density and bFGF on expansion of WJ-MSCs A standardized procedure was utilized to isolate WJ-MSCs from term umbilical cord (Nekanti et al., 2010) . To compare different seeding densities, WJ-MSCs, isolated from three different umbilical cord samples, were plated at 1000, 2000, 3000, and 5000 cells/cm 2 . Next they were cultured in DMEM-KO supplemented with 10% FBS for eight passages and total cell numbers were plotted (Fig. 1A) , respectively. Passaging density affected WJ-MSCs' proliferation potential and lower densities resulted in higher proliferation rates. The mean of population doublings (PD) at each subcultivation was plotted and an increase in number of PD resulted from reducing the initial seeding density. Seeding densities of 5000 and 1000 cells/cm 2 corresponded to 2.36 ± 0.05 and 3.92 ± 0.11 mean PDs (Pb 0.001), respectively (Fig. 1B) .
Next WJ-MSCs (n= 4) were plated at 1000 cells/cm 2 with 10% FBS, plain or supplemented with 2 and 4 ng/ml bFGF. Cells were cultured for five passages under the respective culture conditions. Supplementation of WJ-MSC culture media with bFGF increased the proliferation rate. The optimal condition was represented by 2 ng/ml bFGF. After five passages we obtained 5.17 × 10 9 ±7.89×10 8 and 9.64 ×10 10 ±4.02×10 10 expanded MSCs (data not shown) corresponding to mean PD times of 26.44 ±1.22 and 20.01± 0.32 h (P= 0.0027) for no bFGF and 2 ng/ml bFGF-treated cultures, respectively. WJ-MSCs treated with 2 ng/ml of bFGF displayed higher cumulative population doublings reaching a peak of 22.68 ± 0.75 compared to untreated WJ-MSCs with a peak of 18.92 ± 0.25 (P =0.006) at passage 5. No additional significant increase in cumulative PD (PN 0.05) or mean PD time (PN 0.05) was attained at the end of five passages by further increase in the bFGF concentration from 2 to 4 ng/ml (Figs. 1C and D) .
Based on these experimental results, a seeding density of 1000 cells/cm 2 and 2 ng/ml bFGF were selected for the subsequent experiments.
Clinical-scale expansion procedure MSC cultures were successfully established from five umbilical cord samples. After isolation, WJ-MSCs were plated without counting into a T75 flask in DMEM-KO supplemented with 10% FBS and 2 ng/ml bFGF. After 9-10 days of primary culture, cells were counted and reseeded at 1000 cells/cm 2 onto 2 Cell-STACKS for clinical-scale expansion under the same medium conditions, guided by the previously described experiments.
The amounts of 2.48 × 10 8 ±1.43×10 8 cells were recovered from the clinical-scale cultures which corresponded todoubling time of 22.93 ± 0.94 h and underwent 5.80 ± 0.27 PDs over the 5-day culture period (Fig. 2A) . Hence, primary culture (P0) was followed by a second expansion step (P1) which is the clinicalscale expansion step. A representative photograph of upscaled WJ-MSC cultures is shown in Fig. 2C . Data of clinical-scale expansions of individual WJ-MSC samples are shown in Table 1 .
To evaluate the clonal expansion capacity of WJ-MSCs, CFU-F assay was initiated using the P1 cells. As shown in Fig. 4 L, WJ-MSCs displayed a CFU-F potential of 29.8 ± 2.8.
A normal karyotype, as assessed by GTG banding, was confirmed in large-scale expanded WJ-MSCs (Fig. 2D ).
Immunophenotype and immunofluorescent analysis of upscaled WJ-MSCs
Flow cytometry revealed that the clinical-scale expanded WJ-MSCs were positive for mesenchymal markers CD 44, CD 73, CD 90, CD 105, CD 146, and CD 166 and negative for hematopoietic stem cell markers CD 34 and CD 45 and human leukocyte antigen (HLA)-DR (Fig. 3 ).
STRO-1 is a cell surface antigen which is expressed by mesenchymal stromal progenitor cells (Gronthos et al., 1994; Jones et al., 2002) . The presence of STRO-1 (Fig. 4G ) was identified in upscaled WJ-MSCs by immunofluorescence. Also, we detected a punctate nuclear staining for Oct-4 ( Fig. 4H ) in these cells. Although OCT-4 is expressed almost exclusively in embryonic stem cells (Suzuki et al., 1990) , it has recently been reported in porcine umbilical cord matrix cells (Carlin et al., 2006) and in amniotic fluid cells (Prusa et al., 2003) . HeLa cells, which were used as a negative control, did not show any observable staining for OCT-4 (Fig. 4J ).
In vitro differentiation potential of WJ-MSCs after clinical-scale expansion
We further investigated if the large-scale expansion had an impact on the in vitro differentiation potential of the WJ-MSCs. We subjected the upscaled WJ-MSCs to adipogenic, osteogenic, and chondrogenic differentiation. Induction of osteogenesis in the upscaled WJ-MSCs resulted in extracellular matrix mineralization which was confirmed by Von Kossa staining (Fig. 4B ) while adipogenic differentiation 
Suppression of mitogen-induced T-cell proliferation by the upscaled WJ-MSCs
To evaluate if the clinical-scale-propagated WJ-MSCs can affect the proliferation of T cells in PBMCs in vitro, PHA-activated PBMCs were incubated with and without a layer of mitomycin C-arrested WJ-MSCs. T-cell proliferation was inhibited when cocultured with WJ-MSCs and the degree of inhibition was directly proportional to the number of WJ-MSCs in the coculture (Fig. 4K) . The data demonstrated that clinical-scale-propagated WJ-MSCs could suppress T-cell proliferation efficiently.
Semiquantitative evaluation by RT-PCR
Upscaled WJ-MSCs at P1 were tested for the presence of the hTERT gene by RT-PCR. No expression was detected (Fig. 5C) . Myc, p53, p21, and p16 expression has been involved in MSC transformation (Tarte et al., 2010) and hence, we compared the mRNA expression levels of p53, p21, p16, and c-Myc in corresponding P0 and P1 (upscaled) passages of the same WJ-MSC samples (Fig. 5A ). Our results revealed no change in expression levels for p53, p21, p16, and c-Myc, between P0 and P1 upscaled WJ-MSCs, in two out of three samples tested. In the third sample, all the above-noted four genes were upregulated after scale-up, i.e., at P1. P0 and upscaled P1 cells were examined for OCT-4 expression by RT-PCR (Fig. 5B) . Except for one sample, where there was an increase, the other two maintained the mRNA level of OCT-4 at P1.
Discussion
Due to their potential for self-renewal and multilineage differentiation potential, MSCs represent a major hope for cell-based therapy and tissue engineering. Again because of their immunomodulatory properties, MSCs can provide clinical benefit toward the treatment of several autoimmune disorders and graft versus host disease. MSCs have been recently isolated from several fetal tissues such as amniotic fluid, placenta, amnion, umbilical cord blood, and Wharton's jelly of the umbilical cord. The umbilical cord is discarded as a medical waste after birth and therefore, both technically and ethically, UC represents a source of MSCs which is readily accessible. Recently umbilical cord was reported to be a richer source of MSCs than umbilical cord blood (Secco et al., 2008) . Also, WJ cells exhibited better rescue of photoreceptors and visual functions as compared to placental stem cells and bone marrow MSCs (Lund et al., 2007) . They originate from the embryonic epiblast and retain a combination of most of the embryonic stem cell and MSC markers in primary culture and early passages (Bongso et al., 2008) . WJ-MSCs have been shown to be therapeutic in several different preclinical animal models of human disease (Troyer and Weiss Wharton's, 2008) . However, to meet the clinical demand, it is important to establish a procedure for generation of sufficient quantity of clinical-grade WJ-MSCs in vitro within a reasonable time frame. Recently, we demonstrated the superiority of DMEM-KO in supporting the in vitro expansion of WJ-MSCs, and could expand WJ-MSCs from a single cord to 4-5 × 10 9 cells in 5-6 passages at a seeding density of 5000 cells/cm 2 (Nekanti et al., 2010) . As, MSCs lose their stem cell characteristics with in vitro culturing, it is better to use them for cell and gene therapy early on (Bonab et al., 2006) . In the present study, using a small-scale culture system, we first established that reducing the WJ-MSC seeding density from 5000 to 1000 cells/cm 2 resulted in an increase in proliferation. Therefore, our results indicate that even in the case of WJ-MSCs, there is an inverse correlation between seeding density and population doublings. A seeding density of 1000 cells/cm 2 resulted in significantly higher population doublings when compared to 2000, 3000, or 5000 cells/cm 2 . We also demonstrated that supplementation of culture medium with 2 ng/ml of bFGF resulted in greater proliferative capacity of the WJ-MSCs. bFGF has been used in therapeutic angiogenesis and shown to be safe and well tolerated in human trials (Aviles et al., 2003; Laham et al., 2000; Ito et al., 2008) , and besides, cells would be washed with DPBS before they are injected for preclinical or clinical studies. A significant gain in cumulative population doublings resulted when including 2 ng/ml bFGF to the culture medium. Increasing the bFGF concentration further, from 2 to 4 ng/ml did not make any significant difference to population doublings or population-doubling time. Hence, using a seeding density of 1000 cells/cm 2 and including 2 ng/ml bFGF in the culture medium which is DMEM-KO, we next expanded WJ-MSCs to a clinical quantity of~10 8 cells within approximately 15 days or passage 1.
An extensive characterization of cell surface marker expression using flow cytometry revealed that the upscaled WJ-MSCs were positive for representative MSC markers such as CD 44, CD 73, CD 90, and CD 105. Recent investigations suggest that MSCs are found as perivascular cells or pericytes ( Crisan et al., 2008; Caplan, 2009) . We found positive expression of CD 146, an endothelial cell antigen also expressed on the surface of pericytes, in the upscaled WJMSCs. The use of bFGF in human BM-MSC cultures resulted in upregulation of HLA-DR along with downregulation of CD44 expression (Sotiropoulou et al., 2006) . Our results demonstrated that the upscaled WJ-MSCs were strongly positive for CD44 while they were negative for HLA-DR, suggesting that bFGF at 2 ng/ml did not affect the expression levels of CD44 or HLA-DR in WJ-MSCs. The upscaled WJ-MSCs also confirmed the expression OCT-4 transcription factor at mRNA as well as protein level and STRO-1, a marker for mesenchymal progenitor cells, at the protein level as detected by immunofluorescence. We further found that the upscaled WJ-MSCs retained multilineage potentiality and could be induced to undergo subsequent adipogenic, osteogenic, and chondrogenic differentiation. They could effectively suppress mitogen-induced T-cell proliferation and also did not bear any chromosomal abnormalities, as assessed by karyotype analysis. Telomerase promotes MSC immortalization and along with other events such as amplified c-Myc expression and accumulated chromosomal abnormalities can result in cell transformation (Miura et al., 2006) . Changes in tumor suppressor and oncogene expression have been linked with murine MSC transformation (Rodriguez et al., 2009) . hTERT expression was undetectable in the upscaled WJ-MSCs at the end of passage 1. On comparing P0 and upscaled P1 cells, we observed an increase in p16 expression in a few of the WJ samples at P1 which could possibly suggest replicative senescence (Tarte et al., 2010) . Therefore, although WJ-MSCs are not known to produce teratomas in immunodeficient mice, it is important to test all clinical-grade MSC samples for in vivo tumorogenesis in animals before they are planned for therapeutic applications. This is the first report of clinical-scale expansion of WJ-MSCs from a single umbilical cord to quantities of more than 10 8 cells within about 2 weeks. In fact, by adding just one more round of expansion, we should be able to generate sufficient quantities of MSCs to treat~50 patients from a single cord, considering that a 75-kg patient needs approximately 2×10 6 MSCs per killigram body weight for transplantation , though an optimal MSC dose needs to be evaluated for the different indications. From a clinical point of view, as this simple procedure does not involve repeated passaging or manipulation, it would bring down the production cost of the "cell drug."
Thus, WJ of umbilical cord may represent a significant alternative source of MSCs for allogeneic cell-based therapies with distinct advantages, such as easy accessibility, no ethical concerns, and painless procedure to donors. For clinical use, pooling of MSCs from three to five different umbilical cords could be envisioned, as merging MSCs from Figure 5 RT-PCR analysis of hTERT, OCT-4, and tumor-suppressor genes. (A, B) Relative mRNA expression levels of OCT-4, c-Myc, p53, p21, and p16, analyzed by RT-PCR, were compared between P0 and P1 upscaled cultures of WJ-MSCs. cDNA from HeLa cell line was used as a positive control for p16 PCR. (C) hTERT expression was not detected in upscaled WJ-MSCs using PCR primers specific for the hTERT gene. NTERA-2, known to express hTERT, was used as a positive control. 18 s ribosomal RNA was used as an internal control. Results of all three independent experiments are shown. different donors would assure constant cell quality and availability (Dahlke et al., 2008) along with improved immunosuppressive function (Samuelsson et al., 2009) . Since the ideal clinical-scale propagation of MSCs would involve the use of animal protein-free defined culture medium, we had attempted propagation of WJ-MSCs in knockout serum replacement (KoSR) as an alternative to replace FBS (Nekanti et al., 2010) . Unfortunately, KoSR did not support the growth of WJ-MSCs. In fact, serum-free medium without the addition of growth factors is, usually, not able to expand MSCs in vitro. Platelets are a rich source of growth factors and the use of pooled human platelet lysate as an alternative to FBS has been investigated for FBSfree propagation of MSCs (Tonti and Mannello, 2008; Reinisch et al., 2007) . Hence, a thorough clinical investigation of which is best, amongs FBS, human serum, or human platelet lysate, needs to be attempted. Currently efforts are on in our laboratory to make our cell drug animal-product free.
Materials and methods

Isolation and culture of WJ-MSCs
Human umbilical cords (n = 15) from both sexes were collected from full-term births after either cesarean section or normal vaginal delivery with informed consent using the guidelines approved by the Institutional Committee for Stem Cell Research and Therapy (ICSCRT) and Institutional Ethics Committee (IEC) at the Manipal Hospital, Bangalore, India. WJ-MSCs were isolated as previously described (Wang et al., 2005) .
For optimization of cell seeding density, WJ-MSCs from three different umbilical cords (n = 3) were plated at passage 1 (P1) on tissue culture plastic plates (BD Biosciences, San Jose, CA; USA) at 1000, 2000, 3000, and 5000 cells/cm 2 in Knock out Dulbecco's modified Eagle's medium (DMEM-KO) (Invitrogen, CA, USA), supplemented with 10% FBS (Hyclone, Victoria, Australia) and 2 mM L-glutamine (Invitrogen). The same lot of serum (Cat. No.SH30084.03, Lot No. GQM0049) was used for all the experiments. For basic fibroblast growth factor optimization experiment, isolated WJ-MSCs from individual cord samples were plated at P1 at defined seeding density of 1000 cells/cm 2 in DMEM-KO with 10% FBS, plain or supplemented with 2 or 4 ng/ml bFGF (Sigma, MO, USA). Cultures were incubated at 37°C with 5% humidified CO 2 . At 70-80% confluence, cultures were trypsinized with 0.05% trypsin/0.53 mM EDTA (Invitrogen). For upscaling experiments, harvested cells at P0 were seeded at density of 1000 cells/cm 2 on 2 CellSTACK chambers (Corning, NY, USA) supplemented with DMEM-KO, 10% FBS, 2 mM L-glutamine, and 2 ng/ml bFGF. On Days 5-6 (at 70-80% confluence) cells were harvested and used for subsequent studies. Additional aliquots were cryopreserved.
Growth kinetics
Growth kinetics was analyzed by calculating population doubling and population-doubling time. Population doublings were calculated using the formula: (2) where NI is the inoculum cell number and NH the cell harvest number. The cumulative population-doubling level was calculated by adding the population doubling for each passage to the population-doubling level of the previous passage.
The population-doubling time was obtained by the formula: TD = tplg2/(lgNH-lgNI). NI is the inoculum cell number, NH is the cell harvest number, and t is the time of the culture (in hours).
Immunophenotyping WJ-MSCs expanded in 2 CellSTACK chambers were taken for flow cytometric analysis. The following anti-human antibodies were used to mark the cell surface markers: CD90-PE, CD73-PE, CD44-PE, CD 146-PE, CD166-PE, CD34-PE, CD45-FITC, and HLADR-FITC (all from BD Pharmingen, CA, USA) and CD105-PE (R&D systems, MN, USA). Mouse isotype antibodies served as control (BD Pharmingen). The number of cells staining positive for a marker was determined by the percentage of cells present within a gate established such that 3% of the positive events measured represented nonspecific binding by the PE or FITC-conjugated isotypematched control. At least 10,000 events were acquired on BD LSR II flow cytometer and the results were analyzed using WIN MDI v2.8 software.
Differentiation
In vitro differentiation of WJ-MSCs after clinical-scale expansion was performed as previously described (Wang et al., 2005) . In brief, osteogenic differentiation was induced in the DMEM-KO media supplemented with 10% (vol/vol) FBS (Hyclone), 2 mM L-glutamine (Invitrogen), 0.1 μM dexamethasone, 10 mM β-glycerophosphate, 0.2 mM ascorbic acid (all reagents from Sigma Aldrich). Mineralized deposits were visualized by Von Kossa staining after 21 days. Cells were fixed with 4% paraformaldehyde (Sigma Aldrich) for 20 min and exposed to 1% silver nitrate (Merck) under bright light for 60 min. Adipogenic differentiation was initiated in DMEM-KO/10% FBS/2 mM glutamine supplemented with 200 μM indomethacin, 0.5 mM 3-isobutyl-1-methylxanthine, 10 μg/ml insulin, and 1 μM dexamethasone (all reagents from Sigma Aldrich). At Day 18, the presence of lipid droplets was confirmed by oil red O stain (Sigma Aldrich) and the nuclei were counterstained with hematoxylin. Chondrogenic differentiation was induced in confluent monolayer cultures of WJ-MSCs using a STEMPRO chondrogenesis differentiation kit (Invitrogen). Differentiated cells were stained with Alcian blue 8GX (Sigma) between 8 and 14 days. Images were captured using a Nikon Eclipse TE2000-U inverted microscope (Nikon, Tokyo, Japan).
Immunofluorescence staining
Upscaled WJ-MSCs at passage 2 were plated on chamberslides (BD Falcon). Next they were fixed in 4% paraformaldehyde (Sigma) for 20 min at room temperature and permeabilized in 0.3% Triton X-100. After blocking in 10% normal rabbit serum/goat serum (Sera Laboratories International Ltd, West Sussex, UK), the cells were incubated with primary antibodies, goat anti-Oct-4 (1.6 μg/ml, R&D Systems), and mouse anti-STRO-1 (10 μg/ml, R&D Systems). Secondary antibodies used were FITC-conjugated rabbit anti-goat IgG and FITC-conjugated goat anti-mouse IgM (1:250, Chemicon, Temecula, CA, USA). For negative control sample, the primary antibody was omitted. Slides were counterstained with 4′,6′-diamidino-2-phenylindole dihydrochloride (DAPI) for 5 min. Fluorescent images were captured using a Nikon-Eclipse-90i microscope (Nikon) and Image-Pro AMS version 6.0 software.
Immunosuppression assay
Upscaled WJ-MSCs were treated with 10 μg/ml mitomycin C (Sigma Aldrich) for 2 h and 30 min at 37°C to inhibit MSC proliferation followed by 5 washes with DMEM-KO medium. The cells were next trypsinized and plated in triplicates onto 96-well plates at 12,500, 6250, 3125, and 1562 cells/well. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. PBMCs were stimulated with 10 μg/ml phytohemagglutinin (PHA, Sigma Aldrich) and 2 × 10 5 activated PBMCs were added per well. PHA-activated PBMCs were cultured in the presence and absence of WJMSCs. Cultures were incubated at 37°C, 5% CO 2 for 72 h. After 72 h cell proliferation was analyzed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT, Sigma Aldrich) assay.
CFU-F assay
WJ-MSCs were collected after enzymatic digestion and seeded, in 6-well tissue culture plates, at 10 cell/cm 2 and in triplicates from each of the three cord samples. After 9 days cells were washed with DPBS, fixed in 1% paraformaldehyde for 20 min, stained with 0.1% toluidine blue (in 1% formaldehyde solution) for 1 h, and then rinsed in tap water. Aggregates of 50 cells or more were defined as CFU-Fs. Data are reported as total colony number per 100 cells.
Karyotype analysis
Karyotyping of upscaled WJ-MSC was carried out using a standard Giemsa staining procedure. At least 20 metaphase spreads were analyzed from each MSC preparation. Images were acquired using a Nikon-Eclipse-90i microscope (Nikon).
RT-PCR analysis
Total cellular RNA was isolated using a mirVana miRNA isolation kit (Ambion, Austin, TX). To eliminate traces of genomic DNA, the RNA samples were treated with DNA-free DNase I (Ambion)) according to the manufacturer instructions. The RNA was reverse-transcribed into cDNA using a High Capacity cDNA reverse transcription kit (Applied Biosystems). PCR amplification was performed using Taq polymerase (Sigma) by following standard procedures. The primer sequences were as follows: hTERT, forward primer, 5′-CCTGCTCAAGCTGACTCGACACCGTG and reverse primer, 5′-GGAAAAGCTGGCCCTGGGGTGGAGC-3′-3′ (446 base pairs [bp] ); c-Myc, forward primer, 5′-AAGACTCCAGCGCCTTCTCTC-3′ and reverse primer, 5′-GTTTTCCAACTCCGGGATCTG-3′ (526 bp); P16, forward primer, 5′-TTATTTGAGCTTTGGTTCTG-3′ and reverse primer, 5′-CCGGCT TTCGTAGTTTTCAT-3′ (354 bp); P21, forward primer, 5′-GAGGCCGGGATGAGTTGGGAGGAG-3′ and reverse primer, 5′-CAGCCGGCGTTTGGAGTGGTAGAA-3′ (220 bp); P53,forward primer, 5′-TTGGATCCATGTTTTGC-CAACTGGCC-3′ and reverse primer, 5′-TTGAATT-CAGGCTCCCCTTTCTTGCG-3′ (488 bp); OCT-4, forward primer, 5′-CGACCATCTGCCGCTTTGAG-3′ and reverse primer, 5′-CCCCCTGTCCCCCATTCCTA-3′ (577 bp); 18 s rRNA, forward primer, 5′-CGGCTACCACATCCAAGGAA-3′ and reverse primer, 5′-GCTGGAATTACCGCGGCT-3′ (186 bp).
Statistical data analysis
Data are presented as mean ± SEM. Comparisons of continuous variables between more than two groups were performed by one-or two-way ANOVA, as applicable, and Bonferroni′s multiple comparison test. Student's t test was performed for comparison of pairs of groups. The cutoff value for significance was 0.05. Data analysis and graphical representations were performed by using GraphPad Prism 5 software (GraphPad, San Diego, CA, USA).
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